Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–2.

PubMed  Google Scholar 

Harrold LR, Salman C, Shoor S, Curtis JR, Asgari MM, Gelfand JM, et al. Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996–2009. J Rheumatol. 2013;40(7):1218–25.

Article  PubMed  PubMed Central  Google Scholar 

Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81(2):112–7.

Article  PubMed  Google Scholar 

Krause ML, Crowson CS, Michet CJ, Mason T, Muskardin TW, Matteson EL. Juvenile idiopathic arthritis in Olmsted County, Minnesota, 1960–2013. Arthritis Rheumatol. 2016;68(1):247–54.

Article  PubMed  PubMed Central  Google Scholar 

Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–78.

Article  CAS  PubMed  Google Scholar 

Nikishina I, Shapovalenko A. Growth retardation in patients with juvenile idiopathic arthritis and growth hormone therapy. Pediatr Rheumatol. 2008;6:P50.

Article  Google Scholar 

Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138–49.

Article  PubMed  Google Scholar 

Hersh A, von Scheven E, Yelin E. Adult outcomes of childhood-onset rheumatic diseases. Nat Rev Rheumatol. 2011;7(5):290–5.

Article  PubMed  PubMed Central  Google Scholar 

Minden K. Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res. 2009;72:20–5.

CAS  PubMed  Google Scholar 

Tollisen A, Selvaag AM, Aulie HA, Lilleby V, Aasland A, Lerdal A, et al. Physical functioning, pain, and health-related quality of life in adults with juvenile idiopathic arthritis: a longitudinal 30-year followup study. Arthritis Care Res (Hoboken). 2018;70(5):741–9.

Article  PubMed  Google Scholar 

Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res (Hoboken). 2019;71(6):717–34.

Article  PubMed  Google Scholar 

Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819–28.

PubMed  Google Scholar 

Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342(11):763–9.

Article  CAS  PubMed  Google Scholar 

Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9):3096–106.

Article  CAS  PubMed  Google Scholar 

Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810–20.

Article  CAS  PubMed  Google Scholar 

Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis. 2010;69(4):718–22.

Article  CAS  PubMed  Google Scholar 

Visvanathan S, Wagner C, Marini JC, Lovell DJ, Martini A, Petty R, et al. The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. Pediatr Rheumatol Online J. 2010;8:24.

Article  PubMed  PubMed Central  Google Scholar 

Brunner HI, Ruperto N, Keltsev V, Alexeeva E, Abud-Mendoza C, Schmeling H, et al. A multi-center, open-label study to assess the pharmacokinetics, efficacy and safety of certolizumab pegol in children and adolescents with moderately to severely active polyarticular-course juvenile idiopathic arthritis: week 24 results [abstract]. Arthritis Rheumatol. 2016;68:947.

Google Scholar 

Horneff G, Klein A, Klotsche J, Minden K, Huppertz HI, Weller-Heinemann F, et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther. 2016;18(1):272.

Article  PubMed  PubMed Central  Google Scholar 

Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2018;77(1):21–9.

Article  CAS  PubMed  Google Scholar 

Diener C, Horneff G. Comparison of adverse events of biologicals for treatment of juvenile idiopathic arthritis: a systematic review. Expert Opin Drug Saf. 2019;18(8):719–32.

Article  CAS  PubMed  Google Scholar 

Ungar WJ, Costa V, Burnett HF, Feldman BM, Laxer RM. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review. Semin Arthritis Rheum. 2013;42(6):597–618.

Article  CAS  PubMed  Google Scholar 

Amarilyo G, Tarp S, Foeldvari I, Cohen N, Pope TD, Woo JM, et al. Biological agents in polyarticular juvenile idiopathic arthritis: a meta-analysis of randomized withdrawal trials. Semin Arthritis Rheum. 2016;46(3):312–8.

Article  PubMed  Google Scholar 

Tarp S, Amarilyo G, Foeldvari I, Christensen R, Woo JM, Cohen N, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology (Oxford). 2016;55(4):669–79.

Article  CAS  PubMed  Google Scholar 

Shepherd J, Cooper K, Harris P, Picot J, Rose M. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(34):1–222.

Article  PubMed  PubMed Central  Google Scholar 

Davies R, Gaynor D, Hyrich KL, Pain CE. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: a systematic review. Semin Arthritis Rheum. 2017;46(5):584–93.

Article  CAS  PubMed  Google Scholar 

Cabrera N, Avila-Pedretti G, Belot A, Larbre JP, Mainbourg S, Duquesne A, et al. The benefit-risk balance for biological agents in juvenile idiopathic arthritis: a meta-analysis of randomized clinical trials. Rheumatology (Oxford). 2020;59(9):2226–36.

Article  CAS  PubMed  Google Scholar 

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-34.

Article  PubMed  Google Scholar 

Rolland C, Lucas S, Horneff G, Ruperto N, Minden K, Curiale C, et al. Assessing the clinical effectiveness and safety of tumour necrosis factor inhibitors (TNFis) for juvenile idiopathic arthritis in the transition from pediatric to adult rheumatology: a systematic review. [Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020162694.

Cochrane. Risk of Bias 2 (RoB 2) tool [Available from: https://methods.cochrane.org/risk-bias-2.

Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202–9.

Article  CAS  PubMed  Google Scholar 

Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658–66.

Article  PubMed  Google Scholar 

Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003;48(1):218–26.

Article  CAS  PubMed  Google Scholar 

Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2006;54(6):1987–94.

Article  PubMed  Google Scholar 

Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58(5):1496–504.

Article  CAS  PubMed  Google Scholar 

Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O’Neil KM, Zeft AS, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64(6):2012–21.

Article  PubMed  Google Scholar 

Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis. 2014;73(6):1114–22.

Article  CAS  PubMed  Google Scholar 

Kingsbury DJ, Bader-Meunier B, Patel G, Arora V, Kalabic J, Kupper H. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin Rheumatol. 2014;33(10):1433–41.

Article